Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Bridging from Intramuscular to Limb Perfusion Delivery of rAAV: Optimization in a Non-human Primate Study.

Gruntman AM, Gernoux G, Tang Q, Ye GJ, Knop DR, Wang G, Benson J, Coleman KE, Keeler AM, Mueller C, Chicoine LG, Chulay JD, Flotte TR.

Mol Ther Methods Clin Dev. 2019 Feb 2;13:233-242. doi: 10.1016/j.omtm.2019.01.013. eCollection 2019 Jun 14.

2.

Prospective Evaluation of Patients With X-Linked Retinoschisis During 18 Months.

Pennesi ME, Birch DG, Jayasundera KT, Parker M, Tan O, Gurses-Ozden R, Reichley C, Beasley KN, Yang P, Weleber RG, Bennett LD, Heckenlively JR, Kothapalli K, Chulay JD, For The Xlrs-Study Group.

Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):5941-5956. doi: 10.1167/iovs.18-24565.

3.

Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 Mice.

Song C, Conlon TJ, Deng WT, Coleman KE, Zhu P, Plummer C, Mandapati S, Van Hoosear M, Green KB, Sonnentag P, Sharma AK, Timmers A, Robinson PM, Knop DR, Hauswirth WW, Chulay JD, Shearman MS, Ye GJ.

Hum Gene Ther Clin Dev. 2018 Dec;29(4):188-197. doi: 10.1089/humc.2018.168.

PMID:
30280954
4.

Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy.

Pennesi ME, Weleber RG, Yang P, Whitebirch C, Thean B, Flotte TR, Humphries M, Chegarnov E, Beasley KN, Stout JT, Chulay JD.

Hum Gene Ther. 2018 Jul 24. doi: 10.1089/hum.2018.014. [Epub ahead of print]

PMID:
29869534
5.

Safety and Efficacy of AAV5 Vectors Expressing Human or Canine CNGB3 in CNGB3-Mutant Dogs.

Ye GJ, Komáromy AM, Zeiss C, Calcedo R, Harman CD, Koehl KL, Stewart GA, Iwabe S, Chiodo VA, Hauswirth WW, Aguirre GD, Chulay JD.

Hum Gene Ther Clin Dev. 2017 Dec;28(4):197-207. doi: 10.1089/humc.2017.125. Epub 2017 Oct 11.

6.

Optimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations.

Beltran WA, Cideciyan AV, Boye SE, Ye GJ, Iwabe S, Dufour VL, Marinho LF, Swider M, Kosyk MS, Sha J, Boye SL, Peterson JJ, Witherspoon CD, Alexander JJ, Ying GS, Shearman MS, Chulay JD, Hauswirth WW, Gamlin PD, Jacobson SG, Aguirre GD.

Mol Ther. 2017 Aug 2;25(8):1866-1880. doi: 10.1016/j.ymthe.2017.05.004. Epub 2017 May 27.

7.

Safety and Efficacy Evaluation of rAAV2tYF-PR1.7-hCNGA3 Vector Delivered by Subretinal Injection in CNGA3 Mutant Achromatopsia Sheep.

Gootwine E, Ofri R, Banin E, Obolensky A, Averbukh E, Ezra-Elia R, Ross M, Honig H, Rosov A, Yamin E, Ye GJ, Knop DR, Robinson PM, Chulay JD, Shearman MS.

Hum Gene Ther Clin Dev. 2017 Jun;28(2):96-107. doi: 10.1089/humc.2017.028. Epub 2017 May 5.

PMID:
28478700
8.

5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency.

Mueller C, Gernoux G, Gruntman AM, Borel F, Reeves EP, Calcedo R, Rouhani FN, Yachnis A, Humphries M, Campbell-Thompson M, Messina L, Chulay JD, Trapnell B, Wilson JM, McElvaney NG, Flotte TR.

Mol Ther. 2017 Jun 7;25(6):1387-1394. doi: 10.1016/j.ymthe.2017.03.029. Epub 2017 Apr 10.

9.

REPEATABILITY AND LONGITUDINAL ASSESSMENT OF FOVEAL CONE STRUCTURE IN CNGB3-ASSOCIATED ACHROMATOPSIA.

Langlo CS, Erker LR, Parker M, Patterson EJ, Higgins BP, Summerfelt P, Razeen MM, Collison FT, Fishman GA, Kay CN, Zhang J, Weleber RG, Yang P, Pennesi ME, Lam BL, Chulay JD, Dubra A, Hauswirth WW, Wilson DJ, Carroll J; ACHM-001 study group.

Retina. 2017 Oct;37(10):1956-1966. doi: 10.1097/IAE.0000000000001434.

10.

Residual Foveal Cone Structure in CNGB3-Associated Achromatopsia.

Langlo CS, Patterson EJ, Higgins BP, Summerfelt P, Razeen MM, Erker LR, Parker M, Collison FT, Fishman GA, Kay CN, Zhang J, Weleber RG, Yang P, Wilson DJ, Pennesi ME, Lam BL, Chiang J, Chulay JD, Dubra A, Hauswirth WW, Carroll J; ACHM-001 Study Group.

Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):3984-95. doi: 10.1167/iovs.16-19313.

11.

Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy.

Weleber RG, Pennesi ME, Wilson DJ, Kaushal S, Erker LR, Jensen L, McBride MT, Flotte TR, Humphries M, Calcedo R, Hauswirth WW, Chulay JD, Stout JT.

Ophthalmology. 2016 Jul;123(7):1606-20. doi: 10.1016/j.ophtha.2016.03.003. Epub 2016 Apr 19.

12.

Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia.

Ye GJ, Budzynski E, Sonnentag P, Nork TM, Miller PE, Sharma AK, Ver Hoeve JN, Smith LM, Arndt T, Calcedo R, Gaskin C, Robinson PM, Knop DR, Hauswirth WW, Chulay JD.

Hum Gene Ther Clin Dev. 2016 Mar;27(1):37-48. doi: 10.1089/humc.2015.164.

13.

Safety and Biodistribution Evaluation in CNGB3-Deficient Mice of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia.

Ye GJ, Budzynski E, Sonnentag P, Nork TM, Miller PE, McPherson L, Ver Hoeve JN, Smith LM, Arndt T, Mandapati S, Robinson PM, Calcedo R, Knop DR, Hauswirth WW, Chulay JD.

Hum Gene Ther Clin Dev. 2016 Mar;27(1):27-36. doi: 10.1089/humc.2015.163.

14.

Recombinant Adeno-Associated Virus Vector Genomes Take the Form of Long-Lived, Transcriptionally Competent Episomes in Human Muscle.

Schnepp BC, Chulay JD, Ye GJ, Flotte TR, Trapnell BC, Johnson PR.

Hum Gene Ther. 2016 Jan;27(1):32-42. doi: 10.1089/hum.2015.136.

15.

Cone-Specific Promoters for Gene Therapy of Achromatopsia and Other Retinal Diseases.

Ye GJ, Budzynski E, Sonnentag P, Nork TM, Sheibani N, Gurel Z, Boye SL, Peterson JJ, Boye SE, Hauswirth WW, Chulay JD.

Hum Gene Ther. 2016 Jan;27(1):72-82. doi: 10.1089/hum.2015.130.

16.

Safety and Biodistribution Evaluation of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin, in RS1-Deficient Mice.

Ye GJ, Conlon T, Erger K, Sonnentag P, Sharma AK, Howard K, Knop DR, Chulay JD.

Hum Gene Ther Clin Dev. 2015 Sep;26(3):177-84. doi: 10.1089/humc.2015.077.

PMID:
26390091
17.

Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin.

Ye GJ, Budzynski E, Sonnentag P, Miller PE, Sharma AK, Ver Hoeve JN, Howard K, Knop DR, Neuringer M, McGill T, Stoddard J, Chulay JD.

Hum Gene Ther Clin Dev. 2015 Sep;26(3):165-76. doi: 10.1089/humc.2015.076. Erratum in: Hum Gene Ther Clin Dev. 2015 Dec;26(4):243. Neuringer, Martha [added]; McGill, Trevor [added]; Stoddard, Jonathan [added].

18.

Herpes simplex virus clearance during purification of a recombinant adeno-associated virus serotype 1 vector.

Ye GJ, Scotti MM, Thomas DL, Wang L, Knop DR, Chulay JD.

Hum Gene Ther Clin Dev. 2014 Dec;25(4):212-7. doi: 10.1089/humc.2014.060.

PMID:
25357151
19.

Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.

Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, Sandhaus RA, McElvaney NG, Messina L, Tang Q, Rouhani FN, Campbell-Thompson M, Fu AD, Yachnis A, Knop DR, Ye GJ, Brantly M, Calcedo R, Somanathan S, Richman LP, Vonderheide RH, Hulme MA, Brusko TM, Wilson JM, Flotte TR.

J Clin Invest. 2013 Dec;123(12):5310-8. doi: 10.1172/JCI70314. Epub 2013 Nov 15.

20.

Development, validation and use of ELISA for antibodies to human alpha-1 antitrypsin.

Ye GJ, Oshins RA, Rouhani FN, Brantly ML, Chulay JD.

J Immunol Methods. 2013 Feb 28;388(1-2):18-24. doi: 10.1016/j.jim.2012.11.008. Epub 2012 Nov 27.

PMID:
23195820
21.

Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results.

Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R, Rouhani F, Campbell-Thompson M, Yachnis AT, Sandhaus RA, McElvaney NG, Mueller C, Messina LM, Wilson JM, Brantly M, Knop DR, Ye GJ, Chulay JD.

Hum Gene Ther. 2011 Oct;22(10):1239-47. doi: 10.1089/hum.2011.053. Epub 2011 Aug 24.

22.

Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method.

Chulay JD, Ye GJ, Thomas DL, Knop DR, Benson JM, Hutt JA, Wang G, Humphries M, Flotte TR.

Hum Gene Ther. 2011 Feb;22(2):155-65. doi: 10.1089/hum.2010.118. Epub 2010 Dec 12.

23.

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

Bernstein DI, Reap EA, Katen K, Watson A, Smith K, Norberg P, Olmsted RA, Hoeper A, Morris J, Negri S, Maughan MF, Chulay JD.

Vaccine. 2009 Dec 11;28(2):484-93. doi: 10.1016/j.vaccine.2009.09.135. Epub 2009 Oct 24.

PMID:
19857446
24.

Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.

Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, Spencer LT, Rouhani F, Conlon TJ, Calcedo R, Betts MR, Spencer C, Byrne BJ, Wilson JM, Flotte TR.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16363-8. doi: 10.1073/pnas.0904514106. Epub 2009 Aug 12. Erratum in: Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17606.

25.

Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.

Hubby B, Talarico T, Maughan M, Reap EA, Berglund P, Kamrud KI, Copp L, Lewis W, Cecil C, Norberg P, Wagner J, Watson A, Negri S, Burnett BK, Graham A, Smith JF, Chulay JD.

Vaccine. 2007 Nov 23;25(48):8180-9. Epub 2007 Oct 5.

26.

Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.

Reap EA, Morris J, Dryga SA, Maughan M, Talarico T, Esch RE, Negri S, Burnett B, Graham A, Olmsted RA, Chulay JD.

Vaccine. 2007 Oct 16;25(42):7441-9. Epub 2007 Aug 30.

27.

Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.

Reap EA, Dryga SA, Morris J, Rivers B, Norberg PK, Olmsted RA, Chulay JD.

Clin Vaccine Immunol. 2007 Jun;14(6):748-55. Epub 2007 Apr 18.

28.

Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection.

Schleiss MR, Lacayo JC, Belkaid Y, McGregor A, Stroup G, Rayner J, Alterson K, Chulay JD, Smith JF.

J Infect Dis. 2007 Mar 15;195(6):789-98. Epub 2007 Feb 6.

PMID:
17299708
29.

Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity.

Lacy MD, Maguire JD, Barcus MJ, Ling J, Bangs MJ, Gramzinski R, Basri H, Sismadi P, Miller GB, Chulay JD, Fryauff DJ, Hoffman SL, Baird JK.

Clin Infect Dis. 2002 Nov 1;35(9):e92-5. Epub 2002 Oct 9.

PMID:
12384852
30.

Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia.

Ling J, Baird JK, Fryauff DJ, Sismadi P, Bangs MJ, Lacy M, Barcus MJ, Gramzinski R, Maguire JD, Kumusumangsih M, Miller GB, Jones TR, Chulay JD, Hoffman SL; Naval Medical Research Unit 2 Clinical Trial Team.

Clin Infect Dis. 2002 Oct 1;35(7):825-33. Epub 2002 Sep 11.

PMID:
12228819
31.

Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model.

Berman JD, Nielsen R, Chulay JD, Dowler M, Kain KC, Kester KE, Williams J, Whelen AC, Shmuklarsky MJ.

Trans R Soc Trop Med Hyg. 2001 Jul-Aug;95(4):429-32.

PMID:
11579890
32.

Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study.

Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, Toovey S, Knobloch J, Nothdurft HD, Shaw D, Roskell NS, Chulay JD; Malarone International Study Team.

Clin Infect Dis. 2001 Oct 1;33(7):1015-21. Epub 2001 Sep 5.

PMID:
11528574
33.

Atovaquone plus proguanil versus halofantrine for the treatment of imported acute uncomplicated Plasmodium falciparum malaria in non-immune adults: a randomized comparative trial.

Bouchaud O, Monlun E, Muanza K, Fontanet A, Scott T, Goetschel A, Chulay JD, Le Bras J, Danis M, Le Bras M, Coulaud JP, Gentilini M.

Am J Trop Med Hyg. 2000 Nov-Dec;63(5-6):274-9.

PMID:
11421377
34.

Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team.

Høgh B, Clarke PD, Camus D, Nothdurft HD, Overbosch D, Günther M, Joubert I, Kain KC, Shaw D, Roskell NS, Chulay JD; Malarone International Study Team.

Lancet. 2000 Dec 2;356(9245):1888-94.

PMID:
11130385
35.

Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand.

Looareesuwan S, Wilairatana P, Glanarongran R, Indravijit KA, Supeeranontha L, Chinnapha S, Scott TR, Chulay JD.

Trans R Soc Trop Med Hyg. 1999 Nov-Dec;93(6):637-40.

PMID:
10717754
36.

Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group.

Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB.

Am J Trop Med Hyg. 1999 Apr;60(4):533-41. Review.

PMID:
10348225
37.

Challenges in the development of antimalarial drugs with causal prophylactic activity.

Chulay JD.

Trans R Soc Trop Med Hyg. 1998 Nov-Dec;92(6):577-9. Review. No abstract available.

PMID:
10326094
38.

Atovaquone and proguanil hydrochloride for prophylaxis of malaria.

Shanks GD, Kremsner PG, Sukwa TY, van der Berg JD, Shapiro TA, Scott TR, Chulay JD; Malarone Clinical Trials Study Group.

J Travel Med. 1999 May;6 Suppl 1:S21-7. Review.

39.

Atovaquone and proguanil hydrochloride for treatment of malaria.

Kremsner PG, Looareesuwan S, Chulay JD.

J Travel Med. 1999 May;6 Suppl 1:S18-20. Review.

40.

Merozoite surface protein-1 epitopes recognized by antibodies that inhibit Plasmodium falciparum merozoite dispersal.

Lyon JA, Carter JM, Thomas AW, Chulay JD.

Mol Biochem Parasitol. 1997 Dec 1;90(1):223-34.

PMID:
9497045
41.
42.

Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge.

Church LW, Le TP, Bryan JP, Gordon DM, Edelman R, Fries L, Davis JR, Herrington DA, Clyde DF, Shmuklarsky MJ, Schneider I, McGovern TW, Chulay JD, Ballou WR, Hoffman SL.

J Infect Dis. 1997 Apr;175(4):915-20.

PMID:
9086149
43.

Plasmodium falciparum: chymotryptic-like proteolysis associated with a 101-kDa acidic-basic repeat antigen.

Nwagwu M, Haynes JD, Orlandi PA, Chulay JD.

Exp Parasitol. 1992 Dec;75(4):399-414.

PMID:
1493872
44.

Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys.

Kelly DJ, Chulay JD, Mikesell P, Friedlander AM.

J Infect Dis. 1992 Nov;166(5):1184-7.

PMID:
1402033
45.

Immunization of owl monkeys with a recombinant protein containing repeated epitopes of a Plasmodium falciparum glycophorin-binding protein.

Aronson NE, Silverman C, Wasserman GF, Kochan J, Hall BT, Esser K, Young JE, Chulay JD.

Am J Trop Med Hyg. 1991 Nov;45(5):548-59.

PMID:
1719834
46.

Molecular basis of sequestration in severe and uncomplicated Plasmodium falciparum malaria: differential adhesion of infected erythrocytes to CD36 and ICAM-1.

Ockenhouse CF, Ho M, Tandon NN, Van Seventer GA, Shaw S, White NJ, Jamieson GA, Chulay JD, Webster HK.

J Infect Dis. 1991 Jul;164(1):163-9.

PMID:
1711552
47.

Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine.

Rickman LS, Gordon DM, Wistar R Jr, Krzych U, Gross M, Hollingdale MR, Egan JE, Chulay JD, Hoffman SL.

Lancet. 1991 Apr 27;337(8748):998-1001.

PMID:
1673211
48.
49.

Host receptors for malaria-infected erythrocytes.

Chulay JD, Ockenhouse CF.

Am J Trop Med Hyg. 1990 Aug;43(2 Pt 2):6-14. Review.

PMID:
1697144
50.

Safety and immunogenicity of a Plasmodium vivax sporozoite vaccine.

Gordon DM, Cosgriff TM, Schneider I, Wasserman GF, Majarian WR, Hollingdale MR, Chulay JD.

Am J Trop Med Hyg. 1990 Jun;42(6):527-31.

PMID:
1695491

Supplemental Content

Loading ...
Support Center